Accessibility Menu
SciSparc logo

SciSparc(NASDAQ) SPRC

Market Cap$3.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year-70%
1 Month-7%
$5.55
-16.29%
-1.08Today
SciSparc last closing stock price
MetricPriceDate
Last closeUSD 6.632026-08-31
SciSparc stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.45%USD 6.662026-08-24
1 month-6.88%USD 7.122026-07-31
3 month-24.05%USD 8.732026-06-02
Year to date-45.83%USD 12.242025-12-31
1 year-70.05%USD 22.142025-08-29
3 year-99.13%USD 762.652023-09-01
5 year-99.98%USD 29,484.002021-09-01
Since inception-99.97%USD 22,113.542021-08-30

SciSparc Financials at a Glance

Market Cap

$3.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$2.16M

Net Income (TTM)

-$18.46M

EPS (TTM)

-$231.49

P/E Ratio

-0.03

Dividend

$0.00

Beta (Volatility)

0.75 (Low)

Price

$5.55

Volume

67,979.376

Open

$6.06

Previous Close

$6.63

Daily Range

$5.56 - $6.22

52-Week Range

$2.98 - $80.10

Estimated Earnings Date

Jul 29, 2026

SPRC News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About SciSparc

SciSparc Ltd. is a pharmaceutical company focused on the clinical development of cannabinoid-derived medications. The company is advancing several drug candidates aimed at treating various medical conditions, including Tourette syndrome, pain, and autism spectrum disorder.

Products and Services
  • SCI-110: Targeting Tourette syndrome and Alzheimer's agitation
  • SCI-160: Designed for pain management
  • SCI-210: Aimed at autism spectrum disorder and epilepsy
Growth Outlook
  • Strategic partnerships enhance development capabilities and market reach
  • Ongoing clinical trials may lead to significant breakthroughs in treatment
  • Potential for expanding product pipeline with new cannabinoid therapies
Financial Highlights
  • Recent quarterly revenue of 395,000, showing a focus on growth
  • Cash and cash equivalents of 4,591,000, providing operational stability
  • Current ratio of 2.41 indicates strong short-term financial health
SciSparc Ltd. operates in the biotechnology sector, leveraging cannabinoid science to develop innovative therapies. The company has established strategic alliances to bolster its research and development efforts, particularly in the areas of neurological and pain-related disorders. With a focus on clinical trials, SciSparc aims to validate its drug candidates and bring them to market, potentially addressing unmet medical needs. The financial position reflects a commitment to growth, with a solid cash reserve and a favorable current ratio, indicating the ability to meet short-term obligations. As the company continues to advance its therapeutic pipeline, it remains positioned for future opportunities in the evolving pharmaceutical landscape.
AI Generated • Aug 23, 2026

Industry

Pharmaceuticals

Employees

3

CEO

Oz Adler, CPA

Headquarters

Tel Aviv, TA 6971916, IL

SPRC Financials

Key Financial Metrics (TTM)

Gross Margin

46.38%

Operating Margin

-1022.08%

Net Income Margin

-1422.78%

Return on Equity

-704.60%

Return on Capital

-189.99%

Return on Assets

-159.79%

Earnings Yield

-33.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$3.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

573.20K

Volume

67.98K

Avg. Volume

335.21K

Financials (TTM)

Gross Profit

$903.00K

Operating Income

-$16.07M

EBITDA

-$15.49M

Operating Cash Flow

-$9.24M

Capital Expenditure

$0.00

Free Cash Flow

-$9.24M

Cash & ST Invst.

$4.59M

Total Debt

$366.00K

SciSparc Performance Analysis

SciSparc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 1,347,000N/A
20232023-12-31USD 2,879,000113.7%
20242024-12-31USD 1,306,000-54.6%
20252025-12-31USD 856,000-34.5%
SciSparc sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-30-7.4%
Q42024-12-31-44.5%
Q22025-06-30-1.1%
Q42025-12-31-14.3%
SciSparc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2,784.08-79.9%
20232023-12-31USD -2,372.69-14.8%
20242024-12-31USD -203.89-91.4%
20252025-12-31USD -882.64332.9%
SciSparc sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-06-3068.9%
Q42024-12-3183.5%
Q22025-06-30-1177.0%
Q42025-12-3156.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$395.00K

-56.4%

Gross Profit

$226.00K

-30.0%

Gross Margin

57.22%

N/A

Market Cap

$3.80MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$1.27M

N/A

Employees

3

N/A

Net Income

-$2.85M

-27.2%

EBITDA

$447.00K

+117.3%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Total Cash

$4.59M

-9.6%

Total Debt

$366.00K

+381.6%

Accounts Receivable

$662.00K

+130.7%

Inventory

$75.00K

-89.9%

Long Term Debt

$0.00

-100.0%

Short Term Debt

$366.00K

+603.8%

Return on Assets

-1.60%

N/A

Return on Invested Capital

-1.63%

N/A

Free Cash Flow

-$2.28M

+14.2%

Operating Cash Flow

-$2.28M

+14.2%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SLRXSalarius Pharmaceuticals, Inc.
$0.84+29.23%
ONCOOnconetix, Inc.
$0.67+6.38%
ARTLArtelo Biosciences, Inc.
$6.10-4.09%
PTIXProtagenic Therapeutics, Inc.
$1.20+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.46-0.05%
NVDANvidia
$219.31-0.01%
BIAFbioAffinity Technologies
$6.70+0.47%
INTCIntel
$89.07-0.00%

Questions About SPRC

What is the current price of SciSparc?

SciSparc is trading at $5.60 per share.

What is the 52-week range for SciSparc?

Over the past 52 weeks, SciSparc has traded between $2.98 and $80.10.

How much debt does SciSparc have?

As of the most recent reporting period, SciSparc reported total debt of $366.00K.

How much cash does SciSparc have on hand?

SciSparc reported $4.61M in cash and cash equivalents in its most recent financial results.

What is SciSparc’s dividend yield?

SciSparc does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.